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Infections causing sepsis, meningitis, or pneumonia 
contributed directly to around 0·6 million neonatal 
deaths worldwide in 2016,1 and indirectly to many more 
through pathways leading to preterm birth and neonatal 
encephalopathy. Despite this knowledge, understanding 
of the causes of neonatal infection, particularly in 
resource-poor settings, is limited. Treatment in these 
settings usually relies on the sensitive but non-specific 
clinical diagnosis of possible serious bacterial infection 
(pSBI),2 made by front-line health-care workers and 
defined according to set criteria. Of the almost 7 million 
neonates needing treatment worldwide each year 
based on this diagnosis,3 most are not tested for specific 
infectious causes and many are likely to have non-
infectious conditions (figure).
In The Lancet, Samir Saha and colleagues report 
the Aetiology of Neonatal Infection in South Asia 
(ANISA) study,4 which is an important step forward in 
understanding the infectious causes of neonatal pSBI. 
The community-based study design is an advance on 
previous studies, which have been mostly facility-
based, and often performed limited microbiological 
investigations. ANISA enrolled 84 971 mothers 
ante natally across five sites in Bangladesh, India, 
and Pakistan, and used community health-care 
workers to follow up neonates after birth. Antenatal 
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patients who discontinued were still in remission almost 
10 months after withdrawal. Thus, stopping the drug 
in patients who are in remission remains an option. 
However, better predictors for outcomes of patients 
who flare on drug holiday are needed. Whether ASDAS 
values in the low range work in this regard needs further 
study. Unfortunately, a third group in which the dose 
was reduced or the interval of injections prolonged 
was not part of this study. This, however, is already 
frequently done in clinical practice and should be 
investigated in the future. The fact that many patients 
who reported clinical flares had normal CRP levels at 
that timepoint also needs further study.
When these results are taken together, this study is 
important because it shows, on the basis of appropriate 
methodology, that continuation of a TNF inhibitor 
has superior outcomes than discontinuation, and this 
was only true for patients who had reached a state of 
inactive disease after 24 weeks of TNF inhibitor therapy. 
However, with almost 50% of patients achieving drug-
free remission, the health system could possibly save 
a lot of money, but how this strategy would influence 
the future course of the disease is not known. Finally, 
the same study in ankylosing spondylitis—which 
has not been done to date—is likely to have different 
results, with a lower proportion of patients in drug-
free remission, because patients of a similar age with 
radiographic axial spondyloarthritis have a higher 
burden of inflammation, even though they report 
similar pain levels.
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recruitment of mothers meant that neonates who 
died shortly after birth were counted and that pSBIs 
were quickly identified by community health-care 
worker follow-up. Systematic sampling and testing 
with conventional and molecular laboratory methods 
maximised pathogen detection. Reductions in 
specificity of diagnosis and identification of multiple 
organisms by molecular diagnostics were mitigated by 
use of control data and Bayesian partially latent class 
modelling to estimate attributable proportions for 
specific infectious causes.
Saha and colleagues’ findings for the causes of 
pSBIs and the non-specificity of this classification as a 
diagnosis are important. Of 6022 pSBI episodes, only 
16% had attributed bacterial causes, and 102 (2%) of 
4859 tested blood samples had clinically significant 
pathogens isolated by culture. More specific clinical 
algorithms and point-of-care diagnostics are needed 
to direct antibiotic treatment to those who need it, 
especially as antibiotic treatment for neonatal pSBI 
is scaled up; WHO guidelines recommend that when 
referral to hospital is not possible, antibiotic treatment 
should be given to outpatients to expand access to 
care.5 Of note, however, this recommendation was 
informed by pragmatic antibiotic trials that used 
pSBI as a clinical diagnosis and tested equivalence of 
regimens.6–8 The ANISA study findings add to concerns 
about the use of non-specific clinical diagnoses for such 
trials9 and underscore the uncertainty in their findings.
As well as what it found, ANISA is important 
for what it did not find. Among 71 361 livebirths, 
3061 (4%) babies died by the end of follow-up, most 
of these soon after birth. Despite active follow-up by 
community health-care workers, only 689 (23%) babies 
who died were assessed by a physician before death, 
and only 349 (11%) had samples taken in the 7 days 
before death.4 Under-representation of deaths is a 
limitation in terms of attributing infectious causes, but 
showing how many neonates who die and who are 
not seen or investigated for infection is important. 
These data are often not captured, or are not reported, 
and the extent to which the sickest neonates in the 
community, in research or in clinical practice, are not 
seen is unknown in many resource-poor settings. 
Improving understanding of the causes of these deaths 
is crucial. Infection is likely to be an important direct 
and indirect contributor, as are preterm birth and 
neonatal encephalopathy. In ANISA, the number of 
attributed infections was nearly double that among 
babies who died than among those who survived, and 
more than 90% of the infectious causes in those who 
died were bacterial.4
Further development of the evidence base to better 
direct interventions towards the highest burden of 
neonatal mortality at and in the few days after birth 
will need new approaches. One such approach is post-
mortem investigation with minimally invasive tissue 
sampling, which may be more acceptable than complete 
diagnostic autopsy and could allow investigation of 
stillbirths and neonates not seen or assessed before 
death.10 The Child Health and Mortality Prevention 
Surveillance study aims to use such techniques.11 Another 
potential approach is the use of maternal vaccines in the 
context of trials, and surveillance after implementation, 
to determine the contributions of specific infectious 
causes. Maternal vaccines are being developed for 
various pathogens, such as respiratory syncytial virus and 
group B streptococcus.12
The ANISA study has advanced understanding of 
neonatal infection and highlighted the limitations 
of current management strategies. Ways to address 
these issues must be urgently sought, and it must be 
remembered that the neonates not seen matter as much 
as those that are.
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Figure: Overlap between possible serious bacterial infections and other clinical syndromes
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How Montgomery is reconfiguring consent in the UK
How should consent be measured? The answer to 
that question will depend on where in the world you 
practise medicine or receive treatment—whether it be 
in a patient-centred health-care service like in Australia 
or a more consumer-driven system such as in the USA. 
In the UK, the validity of consent was until recently 
based on whether a reasonable body of medical opinion 
would agree with it—a principle widely known as the 
Bolam test.1 However, in a 2015 ruling involving a case 
of birth complicated by shoulder dystocia that resulted 
in a child being born with cerebral palsy (Montgomery v 
Lanarkshire Health Board 2015),2 the UK Supreme Court 
declared the Bolam test to be an outdated instance 
of medical paternalism. The Montgomery ruling 
established that doctors must ensure patients are aware 
of any material risks involved in a proposed treatment, 
and of reasonable alternatives. Similar to the Australian 
Canterbury v Spence case of 1972,3 the test of materiality 
was defined as whether a reasonable person in the 
patient’s position would be likely to attach significance 
to the risk, given their individual circumstances. In 
contrast to the Bolam principle, under Montgomery the 
focus lies with the patient and their viewpoint—they 
are now the yardstick by which consent is measured. 
Naturally, this requires an understanding on the part of 
the clinician of what would be deemed a material risk 
to them. The Montgomery standard is being applied 
in the courts and in 2017, for the first time, the Appeal 
Court overturned a High Court judgment based on the 
updated law.4
The Montgomery ruling aimed to guide the medical 
profession towards a new model of shared decision 
making;5 however, doctors are still working out what 
the ruling means in practice.6,7 A 2017 literature search 
by one of us (NH) found that no published studies 
had assessed whether the judgment was changing 
clinical practice.8 One study had explored knowledge of 
consent law and understanding of the relevant changes 
post Montgomery at a large UK teaching hospital, 
finding that most medical staff were not familiar 
with the concept of material risk and recent legal 
developments.7
To address this gap, semi-structured interviews 
were carried out with four barristers and six obstetric 
consultants practising in the UK.8 The aim was to 
examine legal and clinical attitudes towards the updated 
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